Rafferty Asset Management LLC Reduces Holdings in Boston Scientific Corporation $BSX

Key Points

• Rafferty Asset Management LLC reduced its stake in Boston Scientific Corporation by 18.4%, selling 30,681 shares and now holding 136,463 shares, valued at approximately $13.77 million.
• Insider transactions show that Arthur C. Butcher sold 17,313 shares, representing a 42.32% decrease in his position, while Edward J. Ludwig also reduced his ownership by 17.79%.
• Boston Scientific's recent earnings report exceeded expectations with $0.75 earnings per share and a revenue of $5.06 billion, which is a 22.8% year-over-year increase.

Rafferty Asset Management LLC decreased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 18.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,463 shares of the medical equipment provider's stock after selling 30,681 shares during the period. Rafferty Asset Management LLC's holdings in Boston Scientific were worth $13,766,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the period. Highview Capital Management LLC DE grew its stake in Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after buying an additional 1,439 shares during the last quarter. Integrated Wealth Concepts LLC increased its position in Boston Scientific by 2.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 16,140 shares of the medical equipment provider's stock worth $1,442,000 after buying an additional 417 shares during the period. Finally, Kovitz Investment Group Partners LLC lifted its stake in Boston Scientific by 0.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 19,691 shares of the medical equipment provider's stock valued at $1,759,000 after buying an additional 178 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of BSX traded down $0.19 during mid-day trading on Friday, hitting $105.56. The company's stock had a trading volume of 4,066,860 shares, compared to its average volume of 5,967,270. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $79.53 and a 1-year high of $108.94. The firm has a market capitalization of $156.41 billion, a P/E ratio of 62.83, a P/E/G ratio of 2.55 and a beta of 0.66. The firm has a 50-day simple moving average of $104.53 and a 200 day simple moving average of $102.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BSX shares. Barclays raised their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Morgan Stanley lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Truist Financial upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Leerink Partners began coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price target on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $117.50.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.